Vir Biotechnology Inc. (VIR) Prices 7.14M Share Common Offering at $42/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Vir Biotechnology Inc. (VIR) Names Elliott Sigal, M.D., Ph.D. to Board
July 10, 2020 4:03 PM EDTVir Biotechnology, Inc. (NASDAQ: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal formerly served as Executive Vice President, Chief Scientific Officer and President of Bristol-Myers Squibb Company (BMS) Research and Development (R&D), where he played an instrumental role in bringing 14 new medicines to patients in need.
The Vir team is excited to welcome such an accomplished leader to our board of directors, said George Scangos, Ph.D., chief executive officer of Vir. Bringing more than 25 years of invaluable experience in... More
Vir Biotechnology Inc. (VIR) Announces Proposed Public Offering of Common Stock
July 6, 2020 7:03 AM EDTVir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to... More
